Repligen Corp. Stock
Repligen Corp. Stock
Repligen Corp. shows a slight decrease today, losing -€0.350 (-0.250%) compared to yesterday.
We see a rather positive sentiment for Repligen Corp. with 19 Buy predictions and 1 Sell predictions.
As a result the target price of 156 € shows a slightly positive potential of 11.63% compared to the current price of 139.75 € for Repligen Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Repligen Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Repligen Corp. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -0.250% | -2.579% | 1.452% | -11.635% | -0.781% | -14.973% | -21.599% |
| Opko Health Inc. | 0.360% | -4.377% | -0.226% | -22.913% | -2.605% | -23.358% | -72.774% |
| Amicus Therapeutics Inc. | - | 0.000% | 34.066% | 37.079% | 1.667% | 4.901% | -35.789% |
| China Resources Pharmaceutical Group Ltd | 0.400% | 0.810% | 3.320% | -19.677% | 4.622% | -27.299% | 23.267% |
Comments
Repligen (NASDAQ:RGEN) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its price target raised by analysts at Evercore ISI from $155.00 to $175.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for RGEN provided by MarketBeat